The use of sulodexide in obliterating atherosclerosis of the lower extremities in patients with diabetes mellitus

Abstract

Efficacy of sulodexin in diabetics with atherosclerosis obliterans of the lower limbs was assessed from changes in clinical manifestations of intermittent claudication, results of treadmill test, dopplerography of the lower limb vessels, lipidogram, and time course of coagulologic values. Twenty patients with involvement of the lower limb arteries with stages I I-1II according to Fontain were examined. After 10 intramuscular injections of Vessel Due F in a dose of 600 LRU, the drug was administered orally in a dose of 250 LRU twice a day for 12 weeks. Clinical improvement was attained in 88% of patients. The distance of painless walking increased from 152.7+22.2 to 283.6+52.4 m (by 86%), maximal distance from 221.2+29.5 to 376.6+56.9 m (by 70%). Study of changes in coagulologic values over the course of treatment showed increase of activated partial thromboplastin time from 30.7+2.7 to 38.4+1.5 sec (p<0.02), decrease of serum fibrinogen from 4.0+0.1 to 3.2+0.1 g/liter (p<0.003), and increase of thrombin time from 21.7+4.7 to 26.7+3.4 sec (p<0.006). Cholesterol decreased from 6.7+1.0 to 6.27+0.3 mmole/liter (p<.05) and triglycerides showed a tendency to decrease from 1.9+0.23 to 1.7+0.2 mmole/liter (NS). No allergic reactions or side effects were observed during therapy.

Sulodexide for Diabetic-Induced Disabilities: A Systematic Review and Meta-Analysis

“…Signs of retinopathy were monitored as change in hard exudate severity [ 64 ], hard exudate and hemorrhage frequency [ 62 ], incidence of intraocular hemorrhage after panretinal laser coagulation [ 63 ], and rate of recurrence of retinal vein thrombosis [ 65 ]. Vascular complications were monitored using more homogeneous endpoints: pain-free walking distance [ 67 , 69 , 70 ] and maximal walking distance [ 66 , 67 , 69 , 70 ] in PAD, and rate of and time to re-epithelization for diabetes-associated trophic ulcers [ 68 , 71 , 72 ].…”

“…We identified 45 studies that could provide information on the effect of sulodexide in the prevention and/or management of the complications of diabetes, four on ocular complications [62][63][64][65], seven on PAD or diabetesassociated trophic ulcers [66][67][68][69][70][71][72], and 34 on diabetic nephropathy [45,. Data were retrieved from the original published tables or graphs.…”